Sagimet Biosciences director Merdad Parsey will not stand for re-election at 2025 annual meeting

Sagimet Biosciences Inc.

Merdad Parsey, M.D., Ph.D., notified Board on April 29, 2025 he will not seek re-election at the 2025 Annual Meeting scheduled June 9, 2025.
Dr. Parsey will continue as director until the Annual Meeting; departure not due to any disagreement with the Company.
No successor or replacement was announced; board size and composition implications unclear.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Merdad Parsey

Director

SGMT · Sagimet Biosciences Inc.

Effective: 2025-06-09
Filed: April 30, 2025, 7:59 PM ET

On April 29, 2025 Merdad Parsey, M.D., Ph.D., current member of the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), notified the Board that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), currently scheduled to be held on June 9, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Merdad Parsey departed as Director at Sagimet Biosciences Inc..

Action: will not stand for re-election
Role: Director

Exact text from the filing

On April 29, 2025 Merdad Parsey, M.D., Ph.D., current member of the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), notified the Board that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), currently scheduled to be held on June 9, 2025.

View on SEC.gov

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-042566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.